Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 200% increase over the number of companies cited in the previous year.
The citations in the city include:
- You did not establish and maintain procedures for screening of HCT/P donors.
- HCT/P donors were not determined to be eligible based on the results of donor screening and testing.
- After completion of the donor-eligibility determination, HCT/Ps were not accompanied with the summary of the records used to make the donor-eligibility determination.
Most of the companies cited were involved in the Biologics sector.
Of the companies cited, two should take voluntary actions to correct their managing operations (66.7%). Additionally, one company had to take regulatory and/or administrative actions (33.3%).
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
American Red Cross | Biologics | 09/07/2023 | Storage temps./agitation |
Contour Healer, LLC | Devices | 09/15/2023 | Management review - defined interval, sufficient frequency |
Contour Healer, LLC | Devices | 09/15/2023 | Evaluation of suppliers, contractors, etc., requirements |
Contour Healer, LLC | Devices | 09/15/2023 | Lack of or inadequate procedures - Acceptance activities |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Testing, screening, donor eligibility procedures |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Determination based on screening and testing |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Summary--records used to make determination |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Risk factors, clinical evidence |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Abbreviated procedure |
The New Hope Center For Reproductive Medicine | Biologics | 01/20/2023 | Specimen collections not timely |